OCUL News

Ocular Therapeutix™ to Participate in March Investor Conferences

Ocular Therapeutix™ to Present Detailed SOL-1 Data at the 49th Macula Society Annual Meeting and Host Investor Webcast to Discuss Presentations

Ocular Therapeutix Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Ocular Therapeutix™ Reports Positive Results from Landmark SOL-1 Phase 3 Superiority Trial in Wet AMD

Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Corticosteroids Market Report 2026 - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer

Ocular Inflammation and Pain Market & Epidemiology Outlook 2025-2034 Featuring Analysis of DEXTENZA, BYQLOVI and OCS-01 - ResearchAndMarkets.com